OGX-427

On the Horizon – Many More Novel Drugs for the Treatment of Advanced Prostate Cancer

There have been many potential targets identified for the treatment of advanced prostate cancer. Many of these targets are being actively explored with clinical trials designed to test some inhibitors of the targets. Antisense oligonucleotides (OGX-011) targets clusterin, a chaperone protein and OGX-427 which targets heat-shock protein 27 are among the inhibitors being evaluated. OGX-011 [...]

By Malecare|2017-10-19T10:49:43-04:00June 27th, 2013|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Combination Therapy, Custirsen, Drugs & Treatments, General Information, On The Horizon, Tasquinimod (TASQ), Uncategorized, Understanding APC|0 Comments

OncoGenex To Present OGX-427 Data At ASCO 2012 Genitourinary Cancers Symposium

Maybe we are about to have another new treatment for advanced prostate cancer that will earn the coveted descriptor, “ON THE HORIZON.” OncoGenex Pharmaceuticals Inc. (OGXI) has said that they will be presenting preliminary data from their phase 2 trials evaluating their investigational compound OGX-427, in prostate and bladder cancer. The data will be presented [...]

By Malecare|2020-02-04T11:46:20-05:00January 23rd, 2012|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, OGX-427, On The Horizon, Uncategorized|0 Comments